Cargando…

Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review

Epithelial ovarian cancer is a fatal disease, with a cure rate of only 30%. Several recent studies have targeted integrins for cancer treatment. Preclinical studies have shown the effectiveness of several integrin inhibitors for blocking cancer progression, especially by blocking angiogenesis. Becau...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Masaki, Sawada, Kenjiro, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532619/ https://www.ncbi.nlm.nih.gov/pubmed/28698469 http://dx.doi.org/10.3390/cancers9070083

Ejemplares similares

Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer
por: Sawada, Kenjiro, et al.
Publicado: (2012)

Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer
por: Shimizu, Aasa, et al.
Publicado: (2020)

Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target
por: Nakamura, Koji, et al.
Publicado: (2019)

The Role of MicroRNAs in Ovarian Cancer
por: Kinose, Yasuto, et al.
Publicado: (2014)

Clinical relevance of circulating cell-free microRNAs in ovarian cancer
por: Nakamura, Koji, et al.
Publicado: (2016)

A single institution’s experience with minimally invasive surgery for ovarian cancer, and a systematic meta-analysis of the literature
por: Kamei, Yuji, et al.
Publicado: (2023)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types
por: Kobayashi, Masaki, et al.
Publicado: (2018)

Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
por: Nakatsuka, Erika, et al.
Publicado: (2017)

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression
por: Nakamura, Koji, et al.
Publicado: (2019)

Pure Primary Ovarian Squamous Cell Carcinoma Perforating the Rectum
por: Mimura, Kazuya, et al.
Publicado: (2017)

Identification of Malignant Cell Populations Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer Using Single-Cell RNA Sequencing
por: Sumitani, Naoki, et al.
Publicado: (2022)

Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

A case of laparoscopic surgery for endometrial cancer in a patient previously treated with a transvaginal mesh procedure for pelvic organ prolapse
por: Yoshino, Kiyoshi, et al.
Publicado: (2017)

Integrin Inhibitors in Prostate Cancer
por: Juan-Rivera, Maylein C., et al.
Publicado: (2018)

Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives
por: Matsuzaki, Shinya, et al.
Publicado: (2015)

Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer
por: Isobe, Aki, et al.
Publicado: (2015)

Efficacies of uterine artery embolization for symptomatic uterine fibroids using gelatin sponge: a single-center experience and literature review
por: Toda, Aska, et al.
Publicado: (2016)

Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells
por: Roggiani, Francesca, et al.
Publicado: (2016)

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)
por: Oride, Tadashi, et al.
Publicado: (2023)

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma
por: Kinose, Yasuto, et al.
Publicado: (2015)

MicroRNAs Can Influence Ovarian Cancer Progression by Dysregulating Integrin Activity
por: Fasoulakis, Zacharias, et al.
Publicado: (2023)

Melatonin is a potential inhibitor of ovarian cancer: molecular aspects
por: Zare, Hadis, et al.
Publicado: (2019)

Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators
por: Tolomelli, Alessandra, et al.
Publicado: (2017)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review
por: Dhaliwal, Dolly, et al.
Publicado: (2021)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

Emerging therapeutic opportunities for integrin inhibitors
por: Slack, R. J., et al.
Publicado: (2021)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

Hypoxia-inducible ERO1α promotes cancer progression through modulation of integrin-β1 modification and signalling in HCT116 colorectal cancer cells
por: Takei, Norio, et al.
Publicado: (2017)

Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
por: Taylor, Sarah J, et al.
Publicado: (2020)

Integrins and their potential roles in mammalian pregnancy
por: Johnson, Gregory A., et al.
Publicado: (2023)

Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer
por: Ke, Feng‐Yi, et al.
Publicado: (2020)

Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease
por: Stec, Rafał, et al.
Publicado: (2009)

Kinase Inhibitors and Ovarian Cancer
por: Katopodis, Periklis, et al.
Publicado: (2019)

Ligand independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis
por: Mitra, AK, et al.
Publicado: (2010)

Dose–volume analysis of predictors for chronic gastrointestinal complications in patients with cervical cancer treated with postoperative concurrent chemotherapy and whole-pelvic radiation therapy
por: Isohashi, Fumiaki, et al.
Publicado: (2016)

Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review
por: Amano, Tsukuru, et al.
Publicado: (2019)

Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature
por: Whelan, Eilbhe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_185kllpodqauloluik3l9k5fbp